narciclasine has been researched along with Angiogenesis, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bischoff, I; Brandes, RP; Bräutigam, J; Buchmann, G; Epah, J; Fuchs, S; Fürst, R; Heiss, E; Schürmann, C | 1 |
1 other study(ies) available for narciclasine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2.
Topics: Amaryllidaceae; Amaryllidaceae Alkaloids; Angiogenesis Inhibitors; Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Neovascularization, Pathologic; Phenanthridines; Proteoglycans; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2019 |